Medication info
Traglibtin Duo Tablet 2.5/1000mg

Traglibtin Duo Tablet 2.5/1000mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Shinil Pharmaceutical Co., Ltd.
Appearance
Light pink, biconvex, oval film-coated tablet
Packaging
10 tablets/bottle, 30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle, 30 tablets/box (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 201902171 · Approved 2019.04.09 · Insurance code 653806300

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This drug is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior history of pharmacologic treatment for diabetes whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this drug 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this drug 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this drug should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should start at their existing doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this drug should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Patients Requiring Cautious Administration). 5. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this drug should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Patients Requiring Cautious Administration). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic drug to this drug. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use 2. Patients in Whom This Drug Must Not Be Administered).

Ingredients

Manufacturer
Shinil Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication works by combining linagliptin and metformin to help control blood sugar levels in patients with type 2 diabetes. It is designed to be used as an adjunct to diet and exercise, allowing for more effective management of blood sugar. This support aids in better blood sugar control, thereby enhancing the treatment effect for diabetes.

How to take

Adult dose

The dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This drug is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior history of pharmacologic treatment for diabetes whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this drug 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this drug 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this drug should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should start at their existing doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this drug should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Patients Requiring Cautious Administration). 5. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this drug should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Patients Requiring Cautious Administration). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic drug to this drug. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use 2. Patients in Whom This Drug Must Not Be Administered).

Precautions

This medication helps in controlling blood sugar levels. However, rare side effects such as lactic acidosis can occur when taking this medication, which is a serious condition requiring immediate treatment. Individuals who are allergic to any of the ingredients or components of this medication, patients with type 1 diabetes, and those with severe renal impairment should not take this medication. Particularly, it is safer for patients with impaired kidney function, acute infections, dehydration, severely compromised heart or liver function, pregnant women, or breastfeeding women to avoid using this medication. This medication carries a low risk of hypoglycemia when used alone, but the risk may increase when used in conjunction with other hypoglycemic agents such as insulin or sulfonylureas, so caution is necessary. Due to potential deterioration of kidney function, regular blood tests should be conducted to monitor kidney status, and this medication may have to be discontinued if kidney function declines. Additionally, rare side effects like acute pancreatitis or bullous pemphigoid, which presents with skin blisters, can occur, so it is important to consult a doctor immediately if there are abdominal pain or skin abnormalities. During the use of this medication, vitamin B12 levels can decline, so if used long-term, it is advisable to have regular vitamin B12 tests. This medication can interact with certain drugs, so it is essential to inform your doctor or pharmacist if you are taking other medications. Women who are pregnant or considering pregnancy should not use this medication, and those who are breastfeeding should avoid taking it as a precaution. It is recommended that this medication is not used in children under 10 years old or adolescents, as safety and efficacy have not been established. Elderly individuals may have reduced kidney function, so it is advisable to periodically check kidney function and start at the minimal dose when using this medication. There is no research on the effects of this medication on driving or operating machinery, so caution is necessary. In cases of overdose, gastrointestinal disturbances and lactic acidosis may occur, requiring immediate hospital treatment. Store this medication out of reach of children, and keep it dry in its original container.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • taste disturbance
  • cough
  • decreased appetite
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
Show 17 more
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid-like lesions
  • severe joint pain with disability
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • vitamin B12 decrease and deficiency

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a sealed container. It is best to keep the medication at room temperature between 1°C and 30°C. Proper storage will help maintain the medication's effectiveness.

Appearance and packaging

Appearance

Light pink, biconvex, oval film-coated tablet

Package unit

10 tablets/bottle, 30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle, 30 tablets/box (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.